CGS: Industry News
COGSTATE LTD
- Eli Lilly announced positive results from the TRAILBLAZER-ALZ 2 Phase 3 study on their investigational treatment, donanemab, for early symptomatic Alzheimer's disease.
- Lilly plans to proceed with global regulatory submissions and anticipates submitting to the U.S. FDA this quarter while working towards accelerated approvals.
- Cogstate collaborated with Lilly on the TRAILBLAZER-ALZ 2 Phase 3 study and continues to work on advancing neuroscience technology.
2023-05-04 08:29:00